Skip to main content

Advertisement

Table 1 Overview of head to head comparisons amongst GLP-1 analogues and DPP-4 inhibitors.

From: Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus

Study Duration Type GLP-1 analogue DPP-4 inhibitor Co- existing therapy
DeFronzo et al. [31] 4 weeks Double blind, double dummy, cross over Exenatide 5 mcg twice daily for 1st week followed by 10 mcg twice daily for 2nd week Sitagliptin 100 mg once daily Metformin
Berg et al. [32] 8 weeks Double blind, double dummy, cross over Exenatide 10 mcg twice daily Sitagliptin 100 mg once daily none
1860-Lira DPP4 [33] 26 weeks Open label parallel group Liraglutide 1.2 mg and Liraglutide 1.8 mg Sitagliptin 100 mg once daily Metformin
DURATION 2 [35] 26 weeks Double dummy Exenatide QW 2 mg once weekly Sitagliptin 100 mg once daily Metformin
DURATION 4 [37] 26 weeks Double dummy Exenatide QW 2 mg once weekly Sitagliptin 100 mg once daily none
T-emerge 4 [39] 24 weeks Double dummy Taspoglutide 10 mg and 20 mg weekly Sitagliptin 100 mg once daily Metformin
1860- Lira DPP4 extension [34] 52 weeks Open label parallel group Exenatide 10 mcg twice daily Sitagliptin 100 mg once daily Metformin
  1. DDP-4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide 1